LABP Historical PE Ratio image   This LABP PE ratio history page last updated 11/11/2022
LABP PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/10/2022
0.27-0.20-1.37NA
Q2 2022
8/11/2022
1.08-0.28-1.17NA
Q1 2022
5/12/2022
0.67-0.37-1.21NA
Q4 2021
3/24/2022
1.80-0.52-0.84NA
Q3 2021
11/15/2021
14.01-0.32-0.58NA
Q2 2021
7/29/2021
11.280.12NANA
Q1 2021
5/17/2021
11.67-0.38NANA
LABP Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/10/2022
0.27-0.20-0.80NA
Q2 2022
8/11/2022
1.08-0.28-1.12NA
Q1 2022
5/12/2022
0.67-0.37-1.48NA
Q4 2021
3/24/2022
1.80-0.52-2.08NA
Q3 2021
11/15/2021
14.01-0.32-1.28NA
Q2 2021
7/29/2021
11.280.120.4823.5
Q1 2021
5/17/2021
11.67-0.38-1.52NA
Quotes delayed 20 minutes

Email EnvelopeFree LABP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Landos Biopharma (LABP) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

LBPH PE Ratio History
LCI PE Ratio History
LFST PE Ratio History
LGND PE Ratio History
LGVN PE Ratio History
LH PE Ratio History
LHCG PE Ratio History
LHDX PE Ratio History
LIFE PE Ratio History
LIXT PE Ratio History
On this page we presented the LABP PE Ratio History information for Landos Biopharma' stock. The average LABP PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 23.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average LABP PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this LABP PE ratio history result, against the recent PE: when this page was posted on 11/10/2022, the most recent closing price for LABP had been 0.27, and the most recent quarterly earnings result, annualized, was 0.48. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent LABP PE on 11/10/2022 based on annualized quarterly EPS was 0.6. Based on LABP's history, that recent PE is low relative to the historical average, with the recent PE 97.4% lower than the historical average PE across our data set for Landos Biopharma.

For self directed investors doing their due diligence on LABP or any other given stock, valuation analysis for LABP can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Landos Biopharma PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for LABP. Thanks for visiting, and the next time you need to research LABP PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: Top Ten Hedge Funds Holding OILB, ESTA Options Chain, Carnival shares outstanding history.

 

LABP PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.